Company: Alzinova AB
Headquarters: Gothenburg, Sweden
Founded: 2012
Status: Private (pre-revenue)
Focus: Alzheimer's disease immunotherapy
Alzinova AB is a Swedish biotechnology company focused on developing disease-modifying vaccines for Alzheimer's disease. Founded in 2012 and based in Gothenburg, Sweden, Alzinova is pioneering a novel approach to Alzheimer's immunotherapy targeting toxic amyloid oligomers rather than plaques[1].
The company's lead candidate, ALZ-101, is an active immunotherapy (therapeutic vaccine) designed to generate antibodies against toxic amyloid-beta oligomers (AβOs), which are now recognized as the primary pathogenic species in Alzheimer's disease rather than insoluble plaques[2][3]. This approach represents a strategic evolution from earlier amyloid vaccine attempts that targeted plaque material with limited clinical success.
Alzinova was founded in 2012 by a group of Swedish neuroscientists and immunologists based at the University of Gothenburg and Chalmers University of Technology. The company's founding was based on research demonstrating that soluble amyloid-beta oligomers, rather than insoluble plaques, represent the primary neurotoxic species in Alzheimer's disease[4].
Gothenburg, Sweden provides Alzinova with several strategic advantages:
Alzinova operates with a small management team focused on advancing ALZ-101 through clinical development. The company has historically relied on venture capital funding and academic partnerships to advance its programs.
| Program | Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| ALZ-101 | Aβ oligomer vaccine | Alzheimer's Disease | Phase 1 | Active |
| ALZ-201 | Aβ oligomer vaccine (enhanced) | Alzheimer's Disease | Preclinical | Research |
| ALZ-301 | Aβ oligomer-Target | Undisclosed | Discovery | Research |
ALZ-101 represents a next-generation Alzheimer's vaccine approach that differs fundamentally from earlier amyloid vaccination attempts[5][6]:
The shift from plaque-targeting to oligomer-targeting reflects a significant evolution in understanding of Alzheimer's disease pathogenesis[2:1]:
ALZ-101 entered Phase 1 clinical trials, evaluating safety and immunogenicity in patients with mild cognitive impairment (MCI) and early Alzheimer's disease[7][8]. The Phase 1 program includes:
The Phase 1 study is designed to establish:
| Parameter | Goal |
|---|---|
| Safety | Establish maximum tolerated dose |
| Tolerability | Characterize injection site reactions |
| Immunogenicity | Measure antibody titers at each dose level |
| Pharmacokinetics | Assess antibody exposure over time |
| Preliminary efficacy | Exploratory cognitive endpoints |
ALZ-201 is an enhanced version of ALZ-101 designed to:
The company has additional programs in discovery targeting:
Alzinova's approach is grounded in the amyloid oligomer hypothesis, which has become the prevailing framework for understanding Alzheimer's disease pathogenesis[4:1][2:2][3:1]:
Toxic Aβ oligomers cause neurodegeneration through multiple mechanisms:
| Finding | Evidence |
|---|---|
| AβO levels correlate with cognitive decline | Higher CSF AβO in MCI/AD patients |
| AβO injected in animals causes cognitive deficits | Learning/memory impairment in rodents |
| AβO antibodies are protective in models | Passive immunization studies |
| Oligomer-targeted vaccines show efficacy | Preclinical models |
Alzinova's vaccine platform is built on proprietary peptide antigens designed to generate oligomer-specific antibodies[5:1][9]:
| Feature | ALZ-101 | Traditional Aβ Vaccines |
|---|---|---|
| Target | Aβ oligomers | Aβ plaques/monomers |
| Epitope | Conformational | Linear |
| Antibody profile | Anti-oligomer | Broad anti-Aβ |
| Clinical stage | Phase 1 | Mixed (some approved) |
Alzinova maintains research capabilities in:
Alzinova competes in the Alzheimer's immunotherapy space with several approaches:
| Company | Product | Target | Phase | Status |
|---|---|---|---|---|
| Alzinova | ALZ-101 | Aβ oligomers | Phase 1 | Active |
| AC Immune | ACI-35 | Phospho-tau | Phase 1b | Active |
| Arvinas | ARV-102 | Tau | Discovery | Research |
| Vaxxinity | UB-311 | Aβ | Phase 2 | Active |
| Prothelia | PRX012 | Aβ | Phase 1 | Active |
| Company | Product | Target | Status |
|---|---|---|---|
| Eisai/Leqembi | Leqembi | Aβ plaque | Approved |
| Eli Lilly | Donanemab | Aβ plaque | Approved |
| Roche | Gantenerumab | Aβ plaque | Phase 3 |
| AbbVie | ABBV-916 | Aβ | Phase 1 |
Alzinova's differentiation includes:
The company faces several challenges:
The Phase 1 study is structured to establish:
Alzinova is pursuing clinical development under:
If Phase 1 is successful, the company plans:
Alzinova operates as a privately held company with funding from:
The company maintains academic collaborations with:
Alzinova's IP portfolio includes:
The Alzheimer's disease market represents one of the largest pharmaceutical opportunities:
The approval of Leqembi (lecanemab) and Donanemab has validated the amyloid-targeting approach but also created a competitive baseline. Alzinova's oligomer-specific approach could offer advantages in safety and efficacy.
Alzinova AB. Corporate Website. ↩︎
Benilova I, et al. The toxic Aβ oligomer in Alzheimer's disease. 2022. ↩︎ ↩︎ ↩︎ ↩︎
Wirths C, et al. Aβ oligomer hypothesis. 2023. ↩︎ ↩︎ ↩︎
Selkoe DJ. Alzheimer disease in the 21st century. 2019. ↩︎ ↩︎ ↩︎
Cleenwerck S, et al. Active vaccination against Alzheimer's disease. 2020. ↩︎ ↩︎ ↩︎
Sehgal N, et al. Therapeutic vaccines for neurodegenerative diseases. 2023. ↩︎
ALZFORUM Therapeutics Database. Alzinova AB. ↩︎
Espay AJ, et al. Alzheimer's disease prevention trials. 2024. ↩︎
Lamb B, et al. Immunotherapy targeting amyloid oligomers. 2023. ↩︎
Moreth J, et al. Anti-oligomer antibodies for Alzheimer's disease. 2022. ↩︎